The extraordinary amount of $120 million in a round led by TPG Capital, Institutional Venture Partners and T. Rowe Price Associates, was raised by Tanium Inc.

Editas Medicine, a leading genome editing company, raised $120 million in a highly oversubscribed Series B private financing. It is noted that Editas is translating the promise of CRISPR/Cas9 technology into a new class of transformative genomic medicines to treat a broad range of diseases by enabling precise and corrective molecular modifications to treat disease […]